Loading
Eisbach Bio develops small-molecule cancer medicines. Its lead tablet, EIS-12656, blocks a DNA repair enzyme called ALC1 and is in an early trial in advanced solid tumours with defects in DNA repair.
Eisbach Bio GmbH is a privately held clinical-stage company in Martinsried, Planegg, near Munich. It uses an AI-guided platform called ALLOS to design small molecules that target the activated state of enzymes. EIS-12656 is an oral, brain-penetrant, allosteric inhibitor of the chromatin helicase ALC1 (CHD1L), studied in homologous recombination deficient tumours; the phase 1/2 MATCH trial (NCT06525298) at MD Anderson tests it alone and with olaparib or trastuzumab deruxtecan, the first patient was dosed in September 2024, and the trial is co-funded by the Cancer Focus Fund. Other programmes target CHD1 in PTEN-deficient tumours and WRN in MSI-high cancers. The company reported completing a phase 1 trial of the helicase inhibitor EIS-10700 in May 2024 and a CPRIT grant in November 2024. Its first registered cancer trial, NCT06525298, was posted on ClinicalTrials.gov in July 2024.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/